Article
Facing inevitable PARPis resistance: Mechanisms and therapeutic strategies for breast cancer treatment
2023-03-30
Abstract excerpt
Abstract BRCA1/2 gene mutations, which result in a dysfunction of homologous recombination repair, have been discovered in at least 5% of breast cancer (BC) patients with the increase in BC incidence in recent years. PARP inhibitors (PARPis), the first drugs with clinical approval based on synthetic lethality, have been approved to treat BRCA1/2‐mutant BC. However, as with other targeted drugs, PARPis drug resista...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 87ff3c32-d432-5ba5-9aad-b01dcb301e4c
- DOI
- 10.1002/inmd.20220013